H. Lundbeck A/S (HLBBF)
OTCMKTS
· Delayed Price · Currency is USD
5.35
0.00 (0.00%)
At close: Jun 20, 2025
H. Lundbeck Revenue
H. Lundbeck had revenue of 6.24B DKK in the quarter ending March 31, 2025, with 17.91% growth. This brings the company's revenue in the last twelve months to 22.95B, up 13.87% year-over-year. In the year 2024, H. Lundbeck had annual revenue of 22.00B with 10.51% growth.
Revenue (ttm)
22.95B DKK
Revenue Growth
+13.87%
P/S Ratio
1.61
Revenue / Employee
4.02M DKK
Employees
5,707
Market Cap
5.37B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
H. Lundbeck News
- 7 days ago - New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Benzinga
- 7 days ago - New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine - Benzinga
- 6 weeks ago - Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers - Seeking Alpha
- 3 months ago - Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - PRNewsWire
- 6 months ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha
- 8 months ago - Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal - Seeking Alpha
- 9 months ago - Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management - Seeking Alpha
- 9 months ago - NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday - Benzinga